Conference Coverage

Gene therapy promising for reversal of hereditary vision loss


 

FROM EAN 2023

Approval status

Session cochair Gianfranco De Stefano, MD, department of human neuroscience, Sapienza University of Rome, asked Dr. La Morgia about the current approval status of lenadogene nolparvovec.

She said that it was presented to the European Medicines Agency for approval, but the application was withdrawn earlier this year. The “main criticism” was that bilateral improvement was seen even in patients who received only a unilateral injection.

This is “not easily explainable,” said Dr. La Morgia, although it was found that the viral vector was present in the uninjected eye.

There was also a question regarding the heterogeneity of the patient data, which it is hoped will be addressed in future clinical trials.

Commenting after the session, De Stefano said in an interview that the results are “very interesting” and “very promising.”

He pointed out that idebenone may be the only currently available therapy for LHON, but it is “not very effective, and it’s something you give the patient just for the sake of doing something” in light of the possibility that he or she might have “even a small improvement” in eyesight.

However, he believes that lenadogene nolparvovec is a long way from becoming available in the clinic, primarily because longer follow-up is required to determine whether just one injection is enough.

“It may be likely that this gene therapy does not have a long-lasting effect,” he explained.

Currently, the longest follow-up is just 2 years; “I don’t know if there will be a need for repeat injection,” De Stefano said.

No funding was declared. Dr. La Morgia has relationships with Chiesi Farmaceutici, GenSight Biologics, Regulatory Pharma Net, Thenewway, Santhera Pharmaceuticals, First Class srl, Biologix, Stoke Therapeutics, and Reneo.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

High drug costs exclude most neurology patients from cutting-edge treatment
MDedge Neurology
Diagnosing rare disorders
MDedge Neurology
More data back Guillain-Barré risk with Janssen COVID shot
MDedge Neurology
FDA OKs first drug for Rett syndrome
MDedge Neurology
Study compares noninvasive treatments of cutaneous neurofibromas
MDedge Neurology
FDA gives fast-track approval to new ALS drug
MDedge Neurology
U.S. incidence, prevalence of myasthenia gravis is rising
MDedge Neurology
FDA OKs new drug for Fabry disease
MDedge Neurology
Can a repurposed Parkinson’s drug slow ALS progression?
MDedge Neurology
Myasthenia gravis drug gets FDA nod
MDedge Neurology